These oncogenic mutations are seen in the early stages of tumorigenesis, as in benign uveal nevi, and are not associated with molecular class (class 1 or 2) or with metastasis.81,82,83,84,85 Clinical studies have demonstrated improved survival of metastatic uveal melanoma patients with selumetinib, a MEK pathway inhibitor, compared to temozolomide.86 Here, MAP2K7 is linked to uveal melanoma.